Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB.
N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.
Non-pharmacological Interventions on Pain and Quality of Life in Chemotherapy Induced Polyneuropathy: Systematic Review and Meta-Analysis.
Papadopoulou M, Stamou M, Bakalidou D, Moschovos C, Zouvelou V, Zis P, Tzartos J, Chroni E, Michopoulos I, Tsivgoulis G.
In Vivo. 2023 Jan-Feb;37(1):47-56. doi: 10.21873/invivo.13053.
Small-fibre polyneuropathy caused by chemical agent resistant coating.
Marshall B, Sharma Md U, Tsakadze Md N, Rossi Md FH.
BMJ Case Rep. 2021 Jun 1;14(6):e242438. doi: 10.1136/bcr-2021-242438.
Causes of polyneuropathy.
Freemon FR.
Acta Neurol Scand Suppl. 1975;59:3-43.
Nitrofurantoin.
D'Arcy PF.
Drug Intell Clin Pharm. 1985 Jul-Aug;19(7-8):540-7. doi: 10.1177/106002808501900706.
Toxic Neuropathies.
Karam C, Dyck PJ.
Semin Neurol. 2015 Aug;35(4):448-57. doi: 10.1055/s-0035-1558977. Epub 2015 Oct 6.
Organophosphate-induced delayed polyneuropathy.
Lotti M, Moretto A.
Toxicol Rev. 2005;24(1):37-49. doi: 10.2165/00139709-200524010-00003.
Atorvastatin-induced polyneuropathy.
Jacobs MB.
Ann Intern Med. 2004 Jul 6;141(1):77. doi: 10.7326/0003-4819-141-1-200407060-00024.
Fluoroquinolone-Induced Demyelinating Polyneuropathy.
Al-Chalabi M, Martinez Salazar A, Bradshaw A.
J Clin Neuromuscul Dis. 2024 Sep 1;26(1):49-53. doi: 10.1097/CND.0000000000000496.
Atorvastatin-induced polyneuropathy.
Silverberg C.
Ann Intern Med. 2003 Nov 4;139(9):792-3. doi: 10.7326/0003-4819-139-9-200311040-00022.
